They confirmed that relative to i.v. or i.t. administration of the soluble STING, slow release of the drugs from a biodegradable hydrogel at the tumour resection site cured a higher percentage of mice with local breast cancer and reduced metastases. The gene discussed is STING1; the disease is breast carcinoma.